Decision analysis in planning for a polio outbreak in the United States

Pediatrics

Volumn 118, Issue 2, 2006, Pages 611-618

  Jenkins, Pamela C ^a   Modlin, John F ^b  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b CHILDREN S HOSPITAL AT DARTMOUTH   (United States)

Author keywords

Decision making; Outbreak control; Outcomes research; Polio

Indexed keywords

POLIOMYELITIS VACCINE; LIVE VACCINE; ORAL POLIOMYELITIS VACCINE; VIRUS ANTIBODY;

ARTICLE; CONTROLLED STUDY; DECISION MAKING; DISEASE CONTROL; DISEASE TRANSMISSION; DRUG EFFICACY; ERADICATION THERAPY; HUMAN; IMMUNIZATION; IMMUNOGENICITY; PARALYSIS; POLIOMYELITIS; PRIORITY JOURNAL; RISK FACTOR; UNITED STATES; BIOSYNTHESIS; COMPUTER SIMULATION; DECISION SUPPORT SYSTEM; DISASTER PLANNING; EPIDEMIC; IMMUNOLOGY; POLIOMYELITIS VIRUS; PROBABILITY; THEORETICAL MODEL;

ANTIBODIES, VIRAL; COMPUTER SIMULATION; DECISION SUPPORT TECHNIQUES; DISASTER PLANNING; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION SCHEDULE; MODELS, THEORETICAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, INACTIVATED; POLIOVIRUS VACCINE, ORAL; PROBABILITY; UNITED STATES; VACCINES, ATTENUATED;

EID: 33748439837     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-2358     Document Type: Article

References (42)

1. Roberts L. Polio: the final assault? Science. 2004;303:1960-1968
2. World Health Organization. Progress towards interruption of wild poliovirus transmission, January 2004 to March 2005. Week Epidemiol Rec. 2005;80:149-156
3. Centers for Disease Control and Prevention. Poliovirus infections in four unvaccinated children - Minnesota, August-October 2005. MMWR Morb Mortal Wkly Rep. 2005;54:1053-1055
4. World Health Organization. Wild poliovirus, 22 Feb 2005 to 21 Feb 2006. 21 February 2006. Available at: www.polioeradication.org/content/ fixed/casemap.shtml. Accessed February 27, 2006
5. Aylward R, Cochi S. Framework for evaluating the risks of paralytic poliomyelitis after global interruption of wild poliovirus transmission. Bull WHO. 2004;82:40-46
6. Modlin J. Poliomyelitis in the United States: the final chapter? JAMA. 2004;292:1749-1751
7. Cello J, Paul A, Wimmer E. Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science. 2002;297:1016-1018
8. Technical Consultative Group to the World Health Organization on the Global Eradication of Poliomyelitis. "Endgame" issues for the global polio eradication initiative. Clin Infect Dis. 2002;34:72-77
9. NVAC-ACIP Joint Working Group and Centers for Disease Control and Prevention. Ensuring preparedness for potential poliomyelitis outbreaks. Recommendations for the US Poliovirus Vaccine Stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Arch Ped Adol Med. 2004;158:1106-1112
10. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States. MMWR Morb Mort Wkly Rep. 2000;49:1-22
11. Sutter R, Patriarca P, Suleiman A, et al. Attributable risk of DTP (diphtheria and tetanux toxoids and pertussis vaccine) injection in provoking paralytic poliomyelitis during a large outbreak in Oman. J Infect Dis. 1992;165:444-449
12. World Health Organization. Polio Outbreak Spreads Across Yemen. Available at: www.who.int/mediacentre/news/releases/2005/pr19/en/index.html. Accessed May 6, 2005.
13. Caceres V, Sutter R. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis. 2001;33:531-541
14. Detsky A, Naigle G, Krahn M, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 - getting started. Med Decis Making. 1997;17:123-125
15. Weinstein M, Fineberg H. Clinical Decision Analysis. Philadelphia, PA: WB Saunders; 1980
16. TreeAge Pro [computer program]. Williamstown, MA: TreeAge Software, Inc; 2005
17. Oronato I, Modlin J, McBean A, et al. Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis. 1991;163:1-6
18. Nishio O, Ishihara Y, Sakae K, Thoms ML, Losonsky GA, Bernier RH. The trend of acquired immunity with live poliovirus vaccine and the effect of revaccination: follow-up of vaccinees for ten years. J Biol Stand. 1984;12:1-10
19. Kimball A, Barr R, Bauer H, Kleinman H, Johnson EA, Cooney MK. Community spread of orally administered attenuated poliovirus vaccine strains. Pub Health Rep. 1961;76:903-914
20. Gelfand H, LeBlanc D, Potash L, Clemmer DI, Fox JP. The spread of living attenuated strains of polioviruses in 2 communities in southern Louisiana. Am J Public Health. 1960;50:767-778
21. Kew O, Wright P, Agol V, et al. Circulating vaccine-derived polioviruses: current state of knowledge. Bull WHO. 2004;82:16-23
22. Nkowane B, Wassilak S, Orenstein W, et al. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987;257:1335-1340
23. Bijkerk H. Poliomyelitis epidemic in the Netherlands, 1978. Dev Biol Stand. 1979;43:195-206
24. Van Wijngaarden J, van Loon A. The polio epidemic in The Netherlands, 1992/1993. Public Health Rev. 1994;21:107-116
25. McBean A, Thoms M, Albrecht P, et al. The serologic response to oral polio vaccine and enhanced potency inactivated polio vaccines. Am J Epidemiol. 1988;128:615-628
26. Cohen-Abbo A, Culley B, Reed G, et al. Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval. Ped Infect Dis J. 1995;14:100-106
27. Patriarca P, Sutter R, Oostvogel P. Outbreaks of paralytic poliomyelitis, 1976-1995. J Infect Dis. 1997;175:S165-S172
28. Schaap G, Bijkerk H, Coutinho R, et al. The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic. Prog Med Virol. 1984;29:124-140
29. Centers for Disease Control and Prevention. National Immunization Program. Immunization coverage in the US. Available at: www.cdc.gov/nip/ coverage/default.htm#chart. Accessed September 15, 2004.
30. Prevots D, Pascual F, Angellili M, et al. Population immunity to polioviruses among preschool children from four urban low-income communities, United States, 1997-2001. Ped Infect Dis J. 2004;23:1130-1136
31. Tebbens R, Pallansch M, Kew O, et al. A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future. Am J Epidemiol. 2005;162:358-372
32. World Health Organization. Polio Case Count. 16 February 2006. Available at: www.who.int/vaccines/immunization_monitoring/en/diseases/ poliomyelitis/case_count.cfm. Accessed February 27, 2006
33. Chen R, Hausinger S, Dajani A, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. JAMA. 1996;275:1639-1645
34. Modlin J, Halsey N, Thoms M, et al. Humoral and mucosal immunity in infants induced by three sequential IPV-OPV immunization schedules. J Infect Dis. 1997;75:S228-S234
35. Gelfand H, Fox J, LeBlanc D. Observations on natural poliovirus infection in immunized children. Am J Public Health. 1957;47:421-431
36. Gelfand H, LeBlanc D, Potash L, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg. 1959;70:312-327
37. Gelfand H, LeBlanc D, Fox J, et al. Studies on the development of natural immunity to poliomyelitis in Louisiana. II. Description and analysis of episodes of infection observed in study group households. Am J Hyg. 1957;65:367-385
38. Melnick J, Ledinko N. Social serology: antibody levels in a normal young population during an epidemic of poliomyelitis. Am J Hyg. 1951;54:354-382
39. Horstmann D. Clinical aspects of acute poliomyelitis. Am J Med. 1949;6:592
40. Prevots D, Sutter R, Strebel P, et al. Completeness of reporting for paralytic poliomyelitis, United States, 1980 through 1991. Arch Ped Adol Med. 1994;148:479-485
41. Alexander L, Seward J, Santibanez T, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States. JAMA. 2004;292:1696-1701
42. Domok I. Experiences associated with the use of live poliovirus vaccine in Hungary, 1959-1982. Rev Infect Dis. 1984;6(suppl 2):S413-S418